OBJECTIVES: In a 5-year multifactorial risk reduction intervention for healthy men with at least one cardiovascular disease (CVD) risk factor, mortality was unexpectedly higher in the intervention than the control group during the first 15-year follow-up. In order to find explanations for the adverse outcome, we have extended mortality follow-up and examined in greater detail baseline characteristics that contributed to total mortality. DESIGN: Long-term follow-up of a controlled intervention trial. SETTING: The Helsinki Businessmen Study Intervention Trial. PARTICIPANTS AND INTERVENTION: The prevention trial between 1974-1980 included 1,222 initially healthy men (born 1919-1934) at high CVD risk, who were randomly allocated into interventi...
Objectives: To analyse survival, cause specific mortality and cardiovascular morbidity in relation t...
BACKGROUND: In individuals below 65 years of age, primary prevention programs have not been successf...
Background During the design phase of a clinical trial, sample size estimates should take into accou...
OBJECTIVES: In a 5-year multifactorial risk reduction intervention for healthy men with at least one...
Objectives: In a 5-year multifactorial risk reduction intervention for healthy men with at least one...
The Belgian Heart Disease Prevention Project was a controlled, randomized multifactorial interventio...
Background The studies on the association of various midlife risk factors with reaching 90 years or ...
The Finnish Diabetes Prevention Study (DPS) was a randomized controlled trial, which showed that it ...
Background: The Finnish Diabetes Prevention Study (DPS) was a randomized controlled trial, which sho...
BACKGROUND: statin treatment has increased also among people aged 80 years and over, but adverse eff...
Objectives: To explore age at death (AD) for major cardiovascular diseases (CVD) and their risk fact...
Background - National Cholesterol Education Program Adult Treatment Panel III guidelines recommended...
Summary. Background. Systolic blood pressure, total cholesterol and smoking are known predictors of ...
The aim of this study was to evaluate the cardiovascular risk (CVR) factors and morbidity in a sampl...
Background - In individuals below 65 years of age, primary prevention programs have not been success...
Objectives: To analyse survival, cause specific mortality and cardiovascular morbidity in relation t...
BACKGROUND: In individuals below 65 years of age, primary prevention programs have not been successf...
Background During the design phase of a clinical trial, sample size estimates should take into accou...
OBJECTIVES: In a 5-year multifactorial risk reduction intervention for healthy men with at least one...
Objectives: In a 5-year multifactorial risk reduction intervention for healthy men with at least one...
The Belgian Heart Disease Prevention Project was a controlled, randomized multifactorial interventio...
Background The studies on the association of various midlife risk factors with reaching 90 years or ...
The Finnish Diabetes Prevention Study (DPS) was a randomized controlled trial, which showed that it ...
Background: The Finnish Diabetes Prevention Study (DPS) was a randomized controlled trial, which sho...
BACKGROUND: statin treatment has increased also among people aged 80 years and over, but adverse eff...
Objectives: To explore age at death (AD) for major cardiovascular diseases (CVD) and their risk fact...
Background - National Cholesterol Education Program Adult Treatment Panel III guidelines recommended...
Summary. Background. Systolic blood pressure, total cholesterol and smoking are known predictors of ...
The aim of this study was to evaluate the cardiovascular risk (CVR) factors and morbidity in a sampl...
Background - In individuals below 65 years of age, primary prevention programs have not been success...
Objectives: To analyse survival, cause specific mortality and cardiovascular morbidity in relation t...
BACKGROUND: In individuals below 65 years of age, primary prevention programs have not been successf...
Background During the design phase of a clinical trial, sample size estimates should take into accou...